JP2021534184A5 - - Google Patents
Info
- Publication number
- JP2021534184A5 JP2021534184A5 JP2021507917A JP2021507917A JP2021534184A5 JP 2021534184 A5 JP2021534184 A5 JP 2021534184A5 JP 2021507917 A JP2021507917 A JP 2021507917A JP 2021507917 A JP2021507917 A JP 2021507917A JP 2021534184 A5 JP2021534184 A5 JP 2021534184A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- exist
- composition according
- pharmaceutical composition
- exists
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024074284A JP7822065B2 (ja) | 2018-08-17 | 2024-05-01 | 急性肺損傷の処置のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719217P | 2018-08-17 | 2018-08-17 | |
| US62/719,217 | 2018-08-17 | ||
| PCT/US2019/046698 WO2020037146A1 (en) | 2018-08-17 | 2019-08-15 | Compositions and methods for treatment of acute lung injury |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024074284A Division JP7822065B2 (ja) | 2018-08-17 | 2024-05-01 | 急性肺損傷の処置のための組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021534184A JP2021534184A (ja) | 2021-12-09 |
| JPWO2020037146A5 JPWO2020037146A5 (https=) | 2022-08-19 |
| JP2021534184A5 true JP2021534184A5 (https=) | 2022-08-19 |
| JP7483684B2 JP7483684B2 (ja) | 2024-05-15 |
Family
ID=69524874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507917A Active JP7483684B2 (ja) | 2018-08-17 | 2019-08-15 | 急性肺損傷の処置のための組成物および方法 |
| JP2024074284A Active JP7822065B2 (ja) | 2018-08-17 | 2024-05-01 | 急性肺損傷の処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024074284A Active JP7822065B2 (ja) | 2018-08-17 | 2024-05-01 | 急性肺損傷の処置のための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12070483B2 (https=) |
| EP (1) | EP3836953A4 (https=) |
| JP (2) | JP7483684B2 (https=) |
| KR (1) | KR20210046698A (https=) |
| CN (1) | CN112703009B (https=) |
| AU (1) | AU2019321654B8 (https=) |
| BR (1) | BR112021002920A2 (https=) |
| CA (1) | CA3109798A1 (https=) |
| IL (1) | IL280868A (https=) |
| MX (1) | MX2021001877A (https=) |
| WO (1) | WO2020037146A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3109798A1 (en) | 2018-08-17 | 2020-02-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of acute lung injury |
| KR20260034620A (ko) * | 2023-05-05 | 2026-03-11 | 페록시테크 인코포레이티드. | 패혈성 쇼크 치료용 조성물 및 방법 |
| EP4720090A1 (en) * | 2023-05-26 | 2026-04-08 | The Trustees of The University of Pennsylvania | Protective agent against endothelial dysfunction |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861756A (en) * | 1988-03-08 | 1989-08-29 | Merrell Dow Pharmaceuticals Inc. | Synthetic pulmonary surfactant |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| ATE173159T1 (de) | 1992-03-25 | 1998-11-15 | Depomed Systems Inc | Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| WO1997047285A1 (en) | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| CA2389236A1 (en) | 1999-11-02 | 2001-05-10 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| AU2001278864A1 (en) * | 2000-06-30 | 2002-01-30 | University Of Cincinnati | Peptides with antioxidant and antimicrobial properties |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| JP2004532259A (ja) | 2001-05-29 | 2004-10-21 | デポメッド ディベロップメント リミティド | 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法 |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| WO2003090682A2 (en) * | 2002-04-25 | 2003-11-06 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
| EP1764095A1 (en) | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| ES2486321T3 (es) * | 2010-06-18 | 2014-08-18 | Xiberscience Gmbh | Péptidos como agentes activos para estabilizar barreras biológicas |
| US8962570B2 (en) * | 2011-05-17 | 2015-02-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism |
| WO2017180546A1 (en) * | 2016-04-11 | 2017-10-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating and preventing lung disease |
| CA3109798A1 (en) | 2018-08-17 | 2020-02-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of acute lung injury |
-
2019
- 2019-08-15 CA CA3109798A patent/CA3109798A1/en active Pending
- 2019-08-15 WO PCT/US2019/046698 patent/WO2020037146A1/en not_active Ceased
- 2019-08-15 US US17/269,097 patent/US12070483B2/en active Active
- 2019-08-15 EP EP19850140.5A patent/EP3836953A4/en active Pending
- 2019-08-15 CN CN201980060751.3A patent/CN112703009B/zh active Active
- 2019-08-15 JP JP2021507917A patent/JP7483684B2/ja active Active
- 2019-08-15 KR KR1020217007331A patent/KR20210046698A/ko not_active Ceased
- 2019-08-15 MX MX2021001877A patent/MX2021001877A/es unknown
- 2019-08-15 BR BR112021002920-6A patent/BR112021002920A2/pt unknown
- 2019-08-15 AU AU2019321654A patent/AU2019321654B8/en active Active
-
2021
- 2021-02-15 IL IL280868A patent/IL280868A/en unknown
-
2024
- 2024-05-01 JP JP2024074284A patent/JP7822065B2/ja active Active
- 2024-07-16 US US18/773,968 patent/US20250082715A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534184A5 (https=) | ||
| RU2129562C1 (ru) | Производные циклических пептидов или их фармацевтически приемлемые соли, способ получения, фармацевтическая композиция | |
| JP2019194251A5 (https=) | ||
| JP2019196370A5 (https=) | ||
| JP2013543501A5 (https=) | ||
| EP1098906B1 (en) | Peptide analogues of pacap | |
| JP2006514024A5 (https=) | ||
| JP2011518179A5 (https=) | ||
| WO1996012736A3 (en) | COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FILAMENT FORMATION AND NEUROTOXICITY | |
| RU98123833A (ru) | Способы и композиции, используемые для ингибирования ангиогенеза | |
| JP2014521684A5 (https=) | ||
| JP2010500399A5 (https=) | ||
| JP2003509020A5 (https=) | ||
| JP2004518624A5 (https=) | ||
| JP2011500814A5 (https=) | ||
| JP2008521840A5 (https=) | ||
| JP2009520758A5 (https=) | ||
| RU97107853A (ru) | Пептидная специфичность антител к мвр (миелиновому основному белку), содержащая его фармацевтическая композиция и способ лечения рассеянного склероза | |
| JP2006508039A5 (https=) | ||
| JP2002521468A5 (https=) | ||
| JP2017519762A5 (https=) | ||
| KR970701724A (ko) | 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin) | |
| JPWO2020037146A5 (https=) | ||
| JP2004506017A (ja) | 抗真菌剤組合せ使用 | |
| JP4800194B2 (ja) | 乾癬の治療薬を製造するためのカハラリド化合物の使用 |